EBV-associated lymphomas
Conditions
Interventions
EBV-specific T cell treatment group:Infusing EBV-specific T cell
Sponsors
The First Affiliated Hospital of Anhui Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) aged at least 14 years, gender not limited. (2) EBV-associated lymphoma confirmed by histopathological examination (virus nucleic acid testing or immunohistochemistry). (3) relapsed or refractoy EBV-associated lymphoma. (4) the presence of at least one measurable lesion. (5) the Eastern Cooperative Oncology Group (ECOG) scale of performance status is 0-2, estimated survival time is more than 3 weeks. (6) patients agree to participate in the study and sign informed consent
Exclusion criteria
Exclusion criteria: The subject should be excluded if any criterion listed below is met. (1) the central nervous system is involved. (2) a medical history of severe heart disease, including ventricular tachycardia, atrial fibrillation, cardiac block, myocardial infarction within one year, congestive heart failure and coronary heart disease with symptoms requiring medications. (3) renal insufficiency ( serum creatinine >180µmol/L) and/or liver insufficiency (total bilirubin >34 µmol/L, ALT/AST >3 times above the upper limit of normal). (4) participation in any other clinical trial within the last one month. (5) the participation is considered not suitable by the researchers.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The safety; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall response rate;Complete remission rate;Partial remission rate;Progression-free survival;Overall survival; | — |
Countries
China
Contacts
Public ContactRuixiang Xia
Department of Hematology, the First Affiliated Hospital of Anhui Medical University
Outcome results
None listed